Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore  by Lim, Poh Lian & Barkham, Timothy M.S.
International Journal of Infectious Diseases 14 (2010) e511–e513Serologic response to rabies pre-exposure vaccination in persons with potential
occupational exposure in Singapore
Poh Lian Lim a,*, Timothy M.S. Barkhamb
aDepartment of Infectious Diseases, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, 308433 Singapore
bDepartment of Laboratory Medicine, Tan Tock Seng Hospital, Singapore
A R T I C L E I N F O
Article history:
Received 24 June 2009
Received in revised form 11 August 2009
Accepted 11 August 2009
Corresponding Editor:
William Cameron, Ottawa, Canada
Keywords:
Rabies antibody
Occupational exposure
Persistence of immunity
Singapore
S U M M A R Y
Sixty-six animal workers received primary rabies vaccination with puriﬁed Vero cell vaccine (PVRV,
VerorabTM). One year later, 26 (39%) demonstrated antibody titers below the recommendedminimumof
0.5 IU/ml, and required a booster. All 15 of a separate group reporting primary vaccination with at least
one booster had titers above 0.5 IU/ml 1 year later, demonstrating long-termboostable immunity. Rabies
antibody titers should be checked 1 year after primary rabies vaccination in persons at high risk of
frequent rabies exposure. If access to serological surveillance is unavailable, such high-risk individuals
should receive booster vaccination.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Rabies is a viral encephalitis transmitted via exposure to saliva
from infected animals, and is one of the few infectious diseases
with case-fatality rates approaching 100%. Although Singapore has
been rabies-free for several decades, the risk of exposure to rabies
remains present for persons traveling to countries where rabies is
still enzootic. The other group of persons potentially at risk of
rabies includes those with occupational exposures, such as animal
handlers and veterinarians working with agencies such as the
Agrifood & Veterinary Authority (AVA) and Singapore Zoo. The risk
in these workers is different from that encountered by travelers;
exposures are much more frequent, with some dog inspectors
reporting animal bites or scratches every few weeks. Working as
they do at the interface with rabies-enzootic countries in the
region, potential rabies exposures in such workers may go
unrecognized. These persons therefore require a greater degree
of protection than a traveler without occupational risk in whom
exposures are relatively infrequent.
There is a relative paucity of data to guide the long-term
program needs of agencies that have a responsibility to protect
employees who may sustain occupationally related exposures to
rabies. A recent paper from the Health Protection Agency in the UK* Corresponding author. Tel.: +65 6357 7919; fax: +65 6252 4056.
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after primary vaccination and subsequent boosters every 3–5
years.1 However, there are relatively few reports on the persistence
of immunity 1 year after primary vaccination to guide such
recommendations.2 The US Centers for Disease Control and
Prevention (CDC) recommend serology testing be conducted every
2 years and a booster given if rabies antibody levels fall below the
minimum recommended level of 0.5 IU/ml.3 However, serology
testing is unavailable inmany places. More data to support current
recommendations for boosters in animal workers at the interface
with rabies-enzootic regions would be useful.
Recent evidence indicates that previously vaccinated patients
have long-lasting immunity up to 20 years after receiving World
Health Organization-recognized modern tissue culture rabies
vaccines, such as puriﬁed Vero cell rabies vaccine (PVRV) or
human diploid cell vaccine (HDCV).4 Patients who had received
these primary vaccines mounted an accelerated neutralizing
antibody rise to boosters at days 0 and 3.4,5 Although antibody
levels represent only one aspect of the immune response to rabies
vaccination, these data show that boosters provide prompt and
adequate increases in antibody levels when given as post-exposure
prophylaxis. However, for animal workers with unrecognized
exposures, a more important consideration would be maintenance
of adequate antibody levels.
In this paper, we report the serologic response in a cohort of
employees 1 year after they had received pre-exposure rabies
vaccinationwith PVRV for potential occupational risk in Singapore.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Rabies antibody titers in individuals 1 year after rabies boosters
No. Age, years Sex Primary Boost 1 Boost 2 Boost 3 Boost 4 Boost 5 Primary until last
booster (years)
Total
doses
Rabies antibody
titer (IU/ml)
1 53 M 1995 1999 2002 2006 11 6 >4.00
2 44 F 2003 2006 3 4 >4.00
3 29 F 2002 2006 4 4 >4.00
4 37 M 1996 2001 2006 10 5 >4.00
5 58 M 1989 1993 1996 1999 2003 2006 17 8 1.11
6 55 M 1996 2006 10 4 3.35
7 54 M 1990 1994 1997 2000 2003 2006 16 8 3.97
8 59 M 1996 2001 2006 10 5 >4.00
9 52 M 1996 2001 2006 10 5 >4.00
10 58 F 1988 1992 1995 1998 2002 2006 18 8 1.93
11 49 M 1996 2001 2006 10 5 >4.00
12 47 M 2000 2006 6 4 3.44
13 33 M 2002 2006 4 4 >4.00
14 61 F 1986 1996 10 4 1.44
15 36 F 1999 2006 2006 2006 7 6 0.95
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primary and booster vaccinations, by time elapsed from primary
vaccine series, age, and gender.
Patients and methods
The Travelers’ Health and Vaccination Clinic (THVC) at Tan Tock
Seng Hospital is the busiest travel medicine clinic in Singapore,
with 17 980 clinic visits in 2008. It is also the principal rabies pre-
and post-exposure prophylaxis treatment center in the country. A
retrospective convenience sample of patients requiring rabies
vaccination for potential occupational exposures was recruited for
the study. The patients consisted of veterinarians and other animal
workers employed by public agencies in Singapore. This cohort had
received either primary or booster rabies vaccination in 2006 at the
THVC. Serology testing was conducted a year later in 2007, as part
of clinical care, to determine if a minimum protective antibody
titer had been achieved. Demographic data and information
regarding the patients’ rabies vaccination history was obtained.
The institutional review board approved the study before
retrospective data collection started.
Sera were tested for anti-rabies antibody with the PlateliaTM
Rabies II kit at theQueensland Public Health Laboratory, Australia.
Patients were considered to have a minimum protective antibody
titer if they achieved an anti-rabies antibody level of at least
0.5 IU/ml.6
Results
We recruited 82 patients. Of these, 66 had completed primary
rabies vaccination (PVRV, VerorabTM) with three doses in 2006 and
had not had any boosters. Forty (60.6%) had adequate rabies
antibody titers (deﬁned as > 0.5 IU/ml) and 26 (39.4%) had low
titers. The individuals with low titers received a rabies vaccine
booster, with instructions to check their antibody levels again in 2
years. Gender was not a signiﬁcant predictor for having a low titer
1 year after primary vaccination; 88.5% of those with low titers
were male compared to 90% of those with adequate titers. Mean
age was not signiﬁcantly different between the group with low
titers (46 years) and the group with adequate titers (50 years). One
additional person (patient 67) had missed the third dose of the
primary series and had an inadequate titer at his 1-year follow-up
visit. The third dose was subsequently given and he was excluded
from the analysis.
There were 15 patients who had received four or more doses of
rabies vaccine in their lives; all 15 (100%) had adequate titers. The
median time from primary vaccination to the most recent booster
for this group was 10 years (range 3–18 years). Thirteen received arabies booster in our clinic before serologic testing. One opted to
check her titer before getting revaccinated (patient 14, Table 1).
She had an adequate titer and therefore did not need a booster. It is
worthwhile noting that her last booster had been in 1996,
demonstrating adequate titers over a period of 11 years without
further boosting. The 15th patient (patient 15, Table 1)
inadvertently received three rabies boosters in 2006 as part of a
primary series because she did not recall prior rabies vaccination;
however, a review of her records later revealed that she had
received her primary series in 1999.
Discussion
These data show that a substantial minority of vaccinees
(39.4%) had antibody levels below the minimum recommended
level 1 year after primary rabies vaccination with PVRV. Given the
mortality associated with rabies infection and the possibility of
unrecognized exposures, any failure of protection carries serious
implications. Serological surveillance to determine the need for a
booster appears justiﬁed in those with an ongoing need for
protection and unrecognized exposures. This category would
include both veterinarians as well as travelers with extensive
informal animal exposures, such as volunteers in animal sanctu-
aries or expatriates adopting stray animals in rabies-enzootic
areas. In such high-risk persons who lack access to serologic
testing, we recommend providing a routine booster 1 year after
primary rabies vaccination to ensure adequate minimum protec-
tive titers.
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